Within ninety minutes of a single intranasal dose, Semax can increase BDNF expression in the rat hippocampus several-fold — a pharmacological feat that most orally administered nootropics cannot approach. Developed in Russia in the 1980s as a synthetic analog of adrenocorticotropic hormone fragment 4-10, Semax was stripped of its hormonal activity but retained — and amplified — the neurotropic effects of the parent molecule. It has been on Russia’s List of Vital and Essential Drugs for decades, used clinically for ischemic stroke and cognitive disorders, yet remains largely unknown outside Eastern European neurology.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four amino acids (Met-Glu-His-Phe) correspond to the 4-7 fragment of adrenocorticotropic hormone (ACTH), while the C-terminal tripeptide Pro-Gly-Pro is a synthetic addition that dramatically extends the peptide’s half-life by protecting it from enzymatic degradation. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a medicinal product in Russia in 1994.[1]
Unlike full-length ACTH, Semax has no significant effect on cortisol secretion or the hypothalamic-pituitary-adrenal axis. The truncation eliminates steroidogenic activity while preserving — and arguably enhancing — the neurotropic, nootropic, and neuroprotective properties associated with the melanocortin fragment. It is administered as an intranasal solution, typically at 0.1% or 1% concentrations, with the higher-concentration formulation marketed for acute stroke.
How Semax Works
BDNF Upregulation: The most well-characterized molecular effect of Semax is rapid upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus and frontal cortex. A 2008 study by Dolotov and colleagues demonstrated that a single intranasal dose of Semax produced significant increases in BDNF and TrkB protein expression in the rat hippocampus within 1.5 to 3 hours.[2] BDNF is the central molecular substrate of synaptic plasticity, long-term potentiation, and adult neurogenesis — making its rapid pharmacological induction a plausible mechanism for cognitive effects.
NGF Induction: Semax also elevates nerve growth factor (NGF) expression in basal forebrain cholinergic neurons. Shadrina and colleagues demonstrated that intranasal Semax administration produced robust induction of NGF and BDNF mRNA in the rat hippocampus and frontal cortex, with effects detectable within hours and persisting for over a day.[3] The cholinergic system is heavily implicated in attention and working memory, and NGF support of basal forebrain neurons is one of the rationales for Semax use in cognitive impairment.
Melanocortin Receptor Activity: As an ACTH fragment analog, Semax interacts with melanocortin receptors — particularly MC4R, which is widely expressed in the CNS and modulates inflammation, neuronal survival, and energy homeostasis. Melanocortin signaling has documented anti-inflammatory effects in the brain, which may contribute to Semax’s neuroprotective profile in ischemic models.
Dopaminergic and Serotonergic Modulation: Semax modifies the activity of monoaminergic systems, with documented effects on dopamine and serotonin turnover in regions including the striatum and prefrontal cortex. This is consistent with reported effects on attention, motivation, and mood — domains that overlap with stimulant and antidepressant pharmacology but appear to be achieved without direct receptor agonism.
The Pharmacokinetic Rationale for Intranasal Delivery
Peptides face a fundamental delivery problem: they are rapidly degraded by gastrointestinal proteases when taken orally, and even when delivered systemically, they struggle to cross the blood-brain barrier. The intranasal route bypasses both obstacles. The olfactory and trigeminal nerve pathways provide a direct anatomical conduit from the nasal mucosa to the CNS, allowing peptides to reach the brain within minutes without traversing the BBB.
For Semax specifically, intranasal administration produces measurable behavioral and biochemical effects within 15 to 30 minutes of dosing. The C-terminal Pro-Gly-Pro extension protects the active ACTH(4-7) tetrapeptide from rapid degradation by aminopeptidases, extending the duration of action substantially beyond what the parent fragment would achieve. This combination — intranasal delivery plus enzymatic stabilization — is what makes Semax pharmacologically practical where many other neuroactive peptides have failed in translation.
Clinical Evidence
Ischemic Stroke: The strongest clinical evidence for Semax comes from its use in acute ischemic stroke. Gusev and colleagues conducted a multicenter trial demonstrating that intranasal Semax administered during the acute phase of ischemic stroke improved neurological recovery and reduced mortality compared with standard care.[4] The proposed mechanism combines neurotrophic support, anti-inflammatory melanocortin signaling, and modulation of glutamate excitotoxicity. Semax is included in Russian clinical guidelines for stroke management on the basis of this and subsequent trials.
Cognitive and Attentional Effects: Several Russian-language studies have evaluated Semax in patients with cognitive impairment, attention disorders, and post-stroke cognitive deficits, generally reporting improvements in attention, memory, and executive function. The methodological quality of much of this literature is variable by Western standards, but the consistency of findings across decades of clinical use is notable.
Stress and Anxiety: Preclinical work has examined Semax in models of stress and anxiety, with evidence that it attenuates stress-induced behavioral changes and gene expression alterations. Medvedeva and colleagues used transcriptomic analysis to demonstrate that Semax modulates expression of immediate-early genes and stress-responsive pathways in the rat hippocampus following acute administration.[5]
Safety Profile
Semax has a favorable safety record across decades of clinical use in Russia. The most commonly reported side effect is mild nasal irritation from the intranasal vehicle. Because the peptide does not stimulate the HPA axis, it does not produce the cortisol-related effects associated with full-length ACTH. There is no documented dependence liability and no withdrawal syndrome.
Caveats are important. Semax has not undergone FDA-style regulatory review and is not approved for any indication in the United States or European Union. Most clinical data is published in Russian-language journals and has not been independently replicated in large Western trials. Long-term effects of chronic BDNF and NGF upregulation in humans have not been rigorously characterized, and theoretical concerns about sustained neurotrophic stimulation — including effects on tumor biology in susceptible individuals — have not been definitively addressed.
Semax vs Other Cognitive Peptides and Nootropics
vs Selank: Selank is another Russian-developed heptapeptide, derived from tuftsin, with primarily anxiolytic and immunomodulatory effects. Where Semax skews toward attention, memory, and neurotrophic induction, Selank skews toward GABAergic anxiolysis without sedation. The two are sometimes used in combination.
vs Cerebrolysin: Cerebrolysin is a porcine-derived peptide mixture used in similar clinical contexts (stroke, dementia) and also believed to act via neurotrophic mimicry. Semax is a defined synthetic single peptide with a more characterized mechanism, while Cerebrolysin is a complex mixture whose active components remain incompletely identified.
vs Racetams: Piracetam and its analogs modulate cholinergic and glutamatergic transmission at the receptor level, with relatively modest effects on neurotrophin expression. Semax produces a rapid and substantial induction of BDNF that racetams do not match, though racetams have a much larger Western evidence base and oral bioavailability advantages.
vs Exercise: The most potent endogenous inducer of BDNF remains physical exercise. Semax should be understood as a pharmacological supplement to — not a replacement for — the lifestyle inputs that sustain neurotrophic signaling. Exercise produces broader systemic adaptations that no peptide can replicate.
References
- Ashmarin IP, et al. “Nootropic analog of adrenocorticotropin 4-10-semax (15 years experience of design and study).” Zhurnal Vysshei Nervnoi Deyatelnosti im I P Pavlova. 1997;47(2):419-425.
- Dolotov OV, et al. “Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97(s1):82-86.
- Shadrina MI, et al. “Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.” Neuroscience Letters. 2001;308(2):115-118.
- Gusev EI, et al. “Neuroprotective effects of semax in acute ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova. 2005;105(11):3-9.
- Medvedeva EV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228.
